Industry News
Pharmaceutical Industry News
Pfizer is paying top dollar for a…
Pfizer is paying top dollar for a GLP-1 candidate from Fosun. Zealand Pharma penned a platform deal with a brand new Chinese biotech to work on drugs for metabolic diseases. China unveiled its first Commercial
The long-planned legislation…
The long-planned legislation contains "encouraging steps" but is overall "not strong enough to move the needle" on European competitiveness, the European Federation of Pharmaceutical Industries and Associations said in a statement.
After winning an approval decades…
After winning an approval decades in the making last year—and shuffling its executive roster throughout 2025—Geron Corporation is scaling back its head count.
Abbott has put the ball back in…
Abbott has put the ball back in Serena Williams’ court to serve up a high-profile endorsement of the Lingo over-the-counter glucose sensor.
After three decades spent rising…
After three decades spent rising through the ranks of sales and marketing teams at major pharmas, Chris Boulton is taking the top spot at an obesity-focused biotech.
How Long Should You Take Antidepressants?
Clinical guidelines are vague, so we asked psychiatrists what to consider when deciding whether to continue taking these medications.
As part of a multi-year…
As part of a multi-year cost-cutting initiative, Pfizer is “making changes in Switzerland to ensure we have the best strategies and models in place to deliver our medicines and vaccines to patients,” a company spokesperson
About a year and a half after…
About a year and a half after telegraphing plans to shift its headquarters from New Jersey to Philadelphia, CDMO Adare Pharma Solutions appears to be turning out the lights at another facility in the City
After pressure from the FTC, Teva…
After pressure from the FTC, Teva has asked the FDA to delist hundreds of patents on products for asthma, diabetes, chronic obstructive pulmonary disease and for epinephrine autoinjectors, the agency said.
A year after a clutch of major…
A year after a clutch of major pharmas threw their weight behind a new campaign devoted to addressing the serious health disparities facing Black breast cancer patients, “Care for HER” has been shown to have
A new guidance document issued by…
A new guidance document issued by the FDA this week offers recommendations for how makers of prescription biosimilars and biologic reference products should approach promotional advertising and labeling for those meds.
The U.K. is upholding its end of a…
The U.K. is upholding its end of a recent trade deal with the U.S., increasing the island country’s potential spending on new medicines by cutting the rebates paid by pharma companies under a cost-control scheme.
Italian nonprofit Fondazione…
Italian nonprofit Fondazione Telethon's Waskyra is an ex vivo gene therapy that can address the root genetic cause of Wiskott-Aldrich syndrome in children and adults.
Roughly half a year after…
Roughly half a year after introducing the new regulatory pathway, the FDA has greenlit the first drug under its ultra-speedy—and controversial—Commissioner's National Priority Voucher pilot review program. The inaugural approval under the program has gone
Supreme Group has consolidated two…
Supreme Group has consolidated two of the companies it bought during a nine-deal, 18-month splurge, combining Amendola Communications and Health+Commerce to form a PR and communications agency.
Pfizer has rolled out detailed…
Pfizer has rolled out detailed trial data suggesting Tukysa could be part of a new first-line treatment to delay the progression of HER2-positive breast cancer.
Eli Lilly has unveiled the…
Eli Lilly has unveiled the location of the third of its four large-scale manufacturing facilities planned for the U.S. The drugmaker has selected Huntsville, Alabama, as the site of a $6 billion plant that will
With a new edition of a…
With a new edition of a long-running awareness campaign, Genentech is drawing attention to the talents and passions that are helping people with multiple sclerosis thrive.
Bora and Corealis are joining…
Bora and Corealis are joining forces to create a new end-to-end CDMO offering for oral solid dose drug development and production. The strategic alliance will be designed to simplify the drug development process and offer
Returning its stake in Biocon…
Returning its stake in Biocon Biologics allows Viatris to re-enter the biosimilar market it left as a result of its 2022 transaction with Biocon.